gdc
PSSGuide_2021
Liver Cancer

Drugs for Liver Cancer (Hepatocellular Carcinoma)

Here are the drugs and financial support services available to patients receiving treatment for Liver Cancer (Hepatocellular Carcinoma).

Cabometyx (cabozantinib)

Drug company: Exelixis
844-900-3273

Cabometyx is a kinase inhibitor used for the treatment of patients with hepatocellular carcinoma (liver cancer) after they received chemotherapy with Nexavar.

Exelixis Access Services offers 2 financial assistance programs for patients who have been prescribed Cabometyx:

EASE Co-pay Program

Patients with private insurance who are eligible for this program will pay $0 per month for Cabometyx, up to a maximum benefit of $25,000 per year.

EASE Patient Assistance Program

This program provides Cabometyx free of charge to qualifying patients who are uninsured or underinsured.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-427-8663

Cyramza is a human VEGF receptor 2 antagonist used as a single therapy for the treatment of hepatocellular carcinoma (liver cancer) in patients who have an alpha fetoprotein of 400 ng/mL or more after they received chemotherapy with Nexavar.

Lilly Oncology offers 2 financial assistance programs for patients who have been prescribed Cyramza:

Lilly Oncology Infused Products Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 for a dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $63,800 for 1 person; $86,200 for 2 people; $108,600 for 3 people; $131,000 for 4 people; $153,400 for 5 people; or $175,800 for 6 people, this program provides Cyramza at no cost.

Defitelio (defibrotide sodium)

Drug company: Jazz Pharmaceuticals
888-837-4397

Defitelio is used for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a rare and life-threatening liver condition that can occur after hematopoietic stem-cell transplantation in patients with different types of cancers.

Jazz Pharmaceuticals offers 1 financial assistance program for patients who have been prescribed Defitelio:

JazzCares Patient Assistance Program

This program offers Defitelio at no cost for patients who are uninsured or deemed uninsured due to lack of coverage for Defitelio. Program benefits are subject to financial and residency eligibility criteria.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with hepatocellular carcinoma (liver cancer) who previously received treatment with Nexavar.

Merck offers 2 financial assistance programs for patients who have been prescribed Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for a couple, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used as the first-line treatment of patients with unresectable (cannot be removed by surgery) hepatocellular carcinoma (liver cancer).

Eisai offers 2 financial assistance programs for patients who have been prescribed Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription of Lenvima, with a $40,000 annual limit.

Eisai Patient Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Nexavar (sorafenib) Tablets

Drug company: Bayer
866-639-2827

Nexavar is a kinase inhibitor used for the treatment of patients with unresectable hepatocellular carcinoma (liver cancer).

Bayer offers 2 financial assistance programs for patients who have been prescribed Nexavar:

Nexavar $0 Co-Pay Program

With this program, patients with private insurance pay a $0 copay for Nexavar, and the program pays up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Nexavar should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication for up to 12 months.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used, alone or in combination with Yervoy, for the treatment of patients with hepatocellular carcinoma (liver cancer) who have previously received Nexavar.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-ofpocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication (or $50,000 annually for 2 BMS drugs used in combination).

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Stivarga (regorafenib) Tablets

Drug company: Bayer
866-639-2827

Stivarga is a kinase inhibitor used for the treatment of patients with hepatocellular carcinoma (liver cancer) who have received Nexavar.

Bayer offers 2 financial assistance programs for patients who have been prescribed Stivarga:

STIVARGA $0 Co-Pay Program

Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Stivarga should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used, in combination with Avastin, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (liver cancer) who have not received previous systemic therapy.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Tecentriq:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Yervoy (ipilimumab)

Drug company: Bristol Myers Squibb
800-861-0048

Yervoy is a human CTLA-4-blocking antibody used, in combination with Opdivo, for the treatment of patients with hepatocellular cancer (liver cancer) who have previously received Nexavar.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients who have been prescribed Yervoy:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Yervoy. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication (or $50,000 annually for 2 BMS drugs used in combination).

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps pay for Yervoy, may be eligible for help paying for their prescription if they are receiving treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Table. Drugs Prescribed for Liver Cancer (Hepatocellular Carcinoma)

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Cabometyx (cabozantinib)
  • Drug company
  • Exelixis
  • Indications
  • Treatment of patients with liver cancer (hepatocellular carcinoma), after Nexavar
  • Patient support services
  • EASE Co-pay Program
    844-900-3273

    EASE Patient Assistance Program
    844-900-3273


    Drug name (generic name)
  • Defitelio (defibrotide sodium)
  • Drug company
  • Jazz Pharmaceuticals
  • Indication
  • Treatment of hepatic veno-occlusive disease (often associated with cancer-related transplant)
  • Patient support services
  • JazzCares Patient Assistance Program
    888-837-4397


    Drug name (generic name)
  • Lenvima (lenvatinib) Capsules
  • Drug company
  • Eisai
  • Indication
  • First-line treatment of patients with unresectable liver cancer (hepatocellular carcinoma)
  • Patient support services
  • Lenvima $0 Co-pay Program
    866-613-4724

    Eisai Patient Assistance Program
    866-613-4724




    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indication
  • Treatment, in combination with Avastin, of patients with unresectable or metastatic liver cancer (hepatocellular carcinoma) who have not received systemic therapy
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    866-422-2377

    Genentech Patient Foundation
    866-422-2377


Share this:

Last modified: April 8, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country